FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
DE3381783D1
(de)
|
1982-03-03 |
1990-09-13 |
Genentech Inc |
Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
DE69123241T2
(de)
|
1990-12-14 |
1997-04-17 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
IL101147A
(en)
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Change of direction of cellular immunity by chimera receptors
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
WO1994004678A1
(fr)
|
1992-08-21 |
1994-03-03 |
Casterman Cecile |
Immunoglobulines exemptes de chaines legeres
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
DK0758394T3
(da)
|
1994-05-02 |
2003-03-03 |
Bernd Groner |
Bifunktionelt protein, fremstilling og anvendelse
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
DE69634855T2
(de)
|
1995-02-24 |
2006-05-18 |
The General Hospital Corp., Boston |
Neuorientierung der zellulären immunität durch rezeptorchimären
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
US6083502A
(en)
|
1996-01-05 |
2000-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Mesothelium antigen and methods and kits for targeting it
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
AU4055697A
(en)
|
1996-08-16 |
1998-03-06 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
AU744160B2
(en)
|
1996-10-25 |
2002-02-14 |
Cell Genesys, Inc. |
Targeted cytolysis of cancer cells
|
US6673901B2
(en)
|
1997-06-12 |
2004-01-06 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
EP1025228A4
(fr)
|
1997-10-21 |
2002-09-18 |
Human Genome Sciences Inc |
Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
|
US6809184B1
(en)
|
1997-12-01 |
2004-10-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
|
CA2319236A1
(fr)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci
|
ATE298248T1
(de)
|
1998-04-15 |
2005-07-15 |
Brigham & Womens Hospital |
T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
EP1109921A4
(fr)
|
1998-09-04 |
2002-08-28 |
Sloan Kettering Inst Cancer |
Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
|
WO2000023573A2
(fr)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿
|
US7052906B1
(en)
|
1999-04-16 |
2006-05-30 |
Celltech R & D Limited |
Synthetic transmembrane components
|
WO2001003720A2
(fr)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation avec des homologues de ligands et de recepteurs du facteur de necrose tumorale
|
JP4896327B2
(ja)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
Pd−1、b7−4の受容体、およびその使用
|
AU1086501A
(en)
|
1999-10-15 |
2001-04-30 |
Carnegie Institution Of Washington |
Rna interference pathway genes as tools for targeted genetic interference
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
DK1257632T3
(da)
|
2000-02-24 |
2008-01-28 |
Xcyte Therapies Inc |
Samtidig stimulering og opkoncentrering af celler
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
CA2425862C
(fr)
|
2000-11-07 |
2013-01-22 |
City Of Hope |
Cellules immunitaires specifiques a cd19 redirigees
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
AU2002258941A1
(en)
|
2001-04-20 |
2002-11-05 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
US20030171546A1
(en)
|
2001-04-30 |
2003-09-11 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
EP1419179B1
(fr)
|
2001-08-10 |
2010-03-03 |
Aberdeen University |
Domaines de liaison d'antigenes issus de poissons
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
US7638325B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
CA2472341C
(fr)
|
2002-02-01 |
2011-06-21 |
Ariad Gene Therapeutics, Inc. |
Composes contenant du phosphore et utilisations associees
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
JP4638876B2
(ja)
|
2003-05-23 |
2011-02-23 |
ワイス |
Gitrリガンド及びgitrリガンド関連分子及び抗体及びその使用
|
EP1660126A1
(fr)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
|
WO2005019429A2
(fr)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions et procedes permettant d'augmenter la phagocytose ou l'activite des phagocytes
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
JP5070045B2
(ja)
|
2004-05-27 |
2012-11-07 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
新規人工抗原提示細胞およびそれらの用途
|
WO2006083289A2
(fr)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
|
WO2006036445A2
(fr)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Recepteur nk chimerique et traitement anticancereux
|
EP3530321A1
(fr)
|
2004-12-10 |
2019-08-28 |
Peter MacCallum Cancer Institute |
Procédés et compositions d'immunothérapie adoptive
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
CN101213297B
(zh)
|
2005-05-09 |
2013-02-13 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
|
MX2007014474A
(es)
|
2005-05-17 |
2008-02-07 |
Univ Connecticut |
Composiciones y metodos para inmunomodulacion en un organismo.
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
NZ596494A
(en)
|
2006-01-13 |
2013-07-26 |
Us Gov Nat Inst Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
EP1981969A4
(fr)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
Anticorps anti-gitr destines au traitement du cancer
|
US20100105136A1
(en)
|
2006-10-09 |
2010-04-29 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
EP3357338A1
(fr)
|
2007-03-30 |
2018-08-08 |
Memorial Sloan-Kettering Cancer Center |
Expression constitutive de ligands costimulants sur des lymphocytes t transférés de manière adoptive
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 pd-1에 대한 항체
|
ES2466916T3
(es)
|
2007-06-27 |
2014-06-11 |
Admune Therapeutics Llc |
Complejos de IL-15 e IL-15R alfa y usos de los mismos
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
EA018396B1
(ru)
|
2007-10-01 |
2013-07-30 |
Бристоль-Мейерз Сквибб Компани |
Антитела человека, которые связывают мезотелин, и применение таких антител
|
CA2703947C
(fr)
|
2007-10-26 |
2018-12-04 |
Governing Council Of The University Of Toronto |
Methodes therapeutiques et diagnostiques utilisant le tim-3
|
BRPI0819909B8
(pt)
|
2007-11-26 |
2021-05-25 |
Bayer Ip Gmbh |
anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica
|
WO2009097140A1
(fr)
|
2008-01-30 |
2009-08-06 |
Memorial Sloan-Kettering Cancer Center |
Procédés d'immunothérapie tumorale prête à l'emploi utilisant des précurseurs de lymphocytes t allogéniques
|
HUE034465T2
(en)
|
2008-02-11 |
2018-02-28 |
Cure Tech Ltd |
Monoclonal antibodies for tumor treatment
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
EP2257572A1
(fr)
|
2008-03-27 |
2010-12-08 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Anticorps monoclonaux anti-mésothéline humaine
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
EP2331566B1
(fr)
|
2008-08-26 |
2015-10-07 |
City of Hope |
Procédé et compositions pour fonctionnement amélioré d'effecteur antitumoral de lymphocytes t
|
WO2010030002A1
(fr)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
Cellule capable d'exprimer un ligand gitr exogène
|
MX349463B
(es)
|
2008-09-26 |
2017-07-31 |
Univ Emory |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
US9206440B2
(en)
|
2009-01-23 |
2015-12-08 |
Roger Williams Hospital |
Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
|
EP3192811A1
(fr)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Anticorps pd-1 et pd-l1 et leurs utilisations
|
CA2756393C
(fr)
|
2009-03-24 |
2017-06-20 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Anticorps anti-mesotheline
|
ES2563527T3
(es)
|
2009-04-30 |
2016-03-15 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
|
JP2013501817A
(ja)
|
2009-08-14 |
2013-01-17 |
アメリカ合衆国 |
胸腺産出の増大およびリンパ球減少症の治療のためのil−15の使用
|
WO2011028683A1
(fr)
|
2009-09-03 |
2011-03-10 |
Schering Corporation |
Anticorps anti-gitr
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
|
WO2011059836A2
(fr)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
WO2011066342A2
(fr)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Inhibition simultanée de pd-l1/pd-l2
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
ME02505B
(fr)
|
2009-12-29 |
2017-02-20 |
Aptevo Res & Development Llc |
Protéines de liaison hétérodimères et utilisations de celles-ci
|
WO2011097477A1
(fr)
|
2010-02-04 |
2011-08-11 |
The Trustees Of The University Of Pennsylvania |
Icos régule de façon critique l'expansion et la fonction des cellules inflammatoires humaines th17
|
CA2802344C
(fr)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques
|
CA2816379A1
(fr)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Recepteurs cd27 chimeres utilises pour rediriger des lymphocytes t vers des tumeurs malignes positives pour cd70
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
CA3102782A1
(fr)
|
2010-12-14 |
2012-06-21 |
University Of Maryland, Baltimore |
Lymphocytes t exprimant un recepteur d'antigene chimerique anti-etiquette universel et methodes de traitement du cancer
|
AU2012207356A1
(en)
|
2011-01-18 |
2013-08-01 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
WO2012127464A2
(fr)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Lymphocytes t constitutivement activés pour l'utilisation dans une thérapie cellulaire adoptive
|
AU2012230780B2
(en)
|
2011-03-23 |
2016-10-27 |
Fred Hutchinson Cancer Center |
Method and compositions for cellular immunotherapy
|
AU2012236068A1
(en)
|
2011-04-01 |
2013-10-17 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
|
CN107164330A
(zh)
|
2011-04-08 |
2017-09-15 |
贝勒医学院 |
使用嵌合细胞因子受体逆转肿瘤微环境的影响
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
WO2013006490A2
(fr)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Anticorps se liant spécifiquement à tim3
|
WO2013016352A1
(fr)
|
2011-07-25 |
2013-01-31 |
Nationwide Children's Hospital, Inc. |
Produits viraux recombinants et procédés pour inhibition de l'expression de dux4
|
EP2736540B1
(fr)
|
2011-07-29 |
2019-03-13 |
The Trustees Of The University Of Pennsylvania |
Récepteurs de commutation par costimulation
|
WO2013033626A2
(fr)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Produits thérapeutiques ciblant un récepteur nkp30
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
EP2755487B1
(fr)
|
2011-09-16 |
2018-12-19 |
Baylor College Of Medicine |
Ciblage du microenvironnement tumoral au moyen de cellules nkt modifiées
|
WO2013054320A1
(fr)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam)
|
IN2014CN02906A
(fr)
|
2011-10-20 |
2015-07-03 |
Us Health |
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
WO2013074916A1
(fr)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Lymphocytes t car+ génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et/ou le système hla
|
RS61033B1
(sr)
|
2011-11-28 |
2020-12-31 |
Merck Patent Gmbh |
Antitela na pd-l1 i njihova upotreba
|
US9556271B2
(en)
|
2011-12-01 |
2017-01-31 |
The Brigham And Women's Hospital, Inc. |
Anti-CEACAM1 recombinant antibodies for cancer therapy
|
EA201491572A1
(ru)
|
2012-02-22 |
2014-12-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции и способы получения устойчивой популяции t-клеток, используемых для лечения злокачественного новообразования
|
US9714278B2
(en)
|
2012-02-22 |
2017-07-25 |
The Trustees Of The University Of Pennsylvania |
Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
|
CN104136458A
(zh)
|
2012-02-22 |
2014-11-05 |
宾夕法尼亚大学董事会 |
在第二代嵌合抗原受体中cd2信号传导结构域的使用
|
CA3209571A1
(fr)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recepteurs d'antigene chimerique anti-mesotheline
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
JP6482461B2
(ja)
|
2012-07-13 |
2019-03-13 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
投与に関する形質導入t細胞の適合性の評価方法
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
|
BR112015000657B1
(pt)
|
2012-07-13 |
2023-12-05 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula geneticamente modificada para expressar um car
|
WO2014011984A1
(fr)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Gestion de la toxicité de l'activité anti-tumorale de récepteurs d'antigènes chimériques (car)
|
IN2014DN10889A
(fr)
|
2012-07-13 |
2015-09-11 |
Univ Pennsylvania |
|
US20160235787A1
(en)
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
JP2015525781A
(ja)
|
2012-07-31 |
2015-09-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答の調節
|
RS61345B1
(sr)
|
2012-08-20 |
2021-02-26 |
Hutchinson Fred Cancer Res |
Postupak i kompozicije za ćelijsku imunoterapiju
|
US9937205B2
(en)
|
2012-09-04 |
2018-04-10 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
|
WO2014052064A1
(fr)
|
2012-09-27 |
2014-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps dirigés contre la mésothéline et procédés d'induction d'une activité anticancéreuse puissante
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
WO2014055657A1
(fr)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques
|
AU2013329083C1
(en)
|
2012-10-12 |
2018-11-08 |
The Brigham And Women's Hospital, Inc. |
Enhancement of the immune response
|
RU2708032C2
(ru)
|
2013-02-20 |
2019-12-03 |
Новартис Аг |
ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
|
WO2014130635A1
(fr)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Ciblage efficace de la leucémie primaire humaine au moyen de lymphocytes t génétiquement modifiés des récepteurs d'antigènes chimériques anti-cd123
|
EP2970426B1
(fr)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
CA3225453A1
(fr)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Recepteurs antigeniques chimeriques de la mesotheline humaine et leurs utilisations
|
EP3087101B1
(fr)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Récepteur d'antigène chimérique régulable
|
WO2015112626A1
(fr)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
EP3811970A1
(fr)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Récepteur d'antigène chimérique régulable
|
HUE054588T2
(hu)
|
2014-04-07 |
2021-09-28 |
Novartis Ag |
Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
AR101829A1
(es)
|
2014-07-21 |
2017-01-18 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
CA2955154C
(fr)
|
2014-07-21 |
2023-10-31 |
Novartis Ag |
Traitement du cancer a l'aide du recepteur antigenique chimerique anti-cd33
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
EP3193915A1
(fr)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
|
WO2016014501A1
(fr)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Molécules de sortase et leurs utilisations
|
EP4205749A1
(fr)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Cellules contenant un récepteur d'antigène chimérique optimisé en sous-ensemble
|
CA2958200A1
(fr)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
WO2016044605A1
(fr)
|
2014-09-17 |
2016-03-24 |
Beatty, Gregory |
Ciblage de cellules cytotoxiques avec des récepteurs chimériques pour l'immunothérapie adoptive
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
WO2016061368A1
(fr)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions et méthodes pour le traitement de tumeurs malignes b-lymphoïdes
|
IL253149B2
(en)
|
2014-12-29 |
2023-11-01 |
Novartis Ag |
Methods for preparing cells expressing a chimeric receptor antigen
|
WO2016115482A1
(fr)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Promoteurs de phosphoglycérate kinase 1 (pgk) et procédés d'utilisation pour l'expression d'un récepteur antigénique chimérique
|
WO2016126608A1
(fr)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Cellules exprimant car dirigées contre de multiples antigènes tumoraux et leurs utilisations
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
EP4056588A1
(fr)
|
2015-04-08 |
2022-09-14 |
Novartis AG |
Thérapies cd20, thérapies cd22 et thérapies combinées avec une cellule exprimant un récepteur d'antigène chimérique cd19 (car)
|
CA2982996A1
(fr)
|
2015-04-17 |
2016-10-20 |
David Maxwell Barrett |
Procedes pour ameliorer l'efficacite et l'expansion de cellules exprimant un recepteur antigenique chimerique
|
EP3286211A1
(fr)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
WO2017027392A1
(fr)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Traitement du cancer à l'aide des protéines de récepteur cd3 chimères
|
CN108780084B
(zh)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
MX2018003353A
(es)
|
2015-09-17 |
2018-09-17 |
Novartis Ag |
Terapias con celulas cart con una eficacia mejorada.
|
JP7082055B2
(ja)
|
2015-12-22 |
2022-06-07 |
ノバルティス アーゲー |
抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
|
CN117866991A
(zh)
|
2016-10-07 |
2024-04-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|